Recarbrio (imipenem, cilastatin and relebactam)
Status:
Under consideration for negotiation
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of patients with the following infections caused by the designated susceptible Gram-negative microorganisms
Last updated October 7, 2026
Status:
Active negotiation
Manufacturer:
Medison Pharma Canada Inc.
Indication:
For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
Last updated October 7, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
Adults with immunoglobulin G4-related disease
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
For the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.
Last updated October 1, 2026
Lupron Depot (leuprolide acetate)
Status:
Active negotiation
Manufacturer:
AbbVie Corporation
Indication:
Advanced prostate cancer
Last updated September 25, 2026
Status:
Concluded with an LOI
Manufacturer:
BeOne Medicines (Canada) ULC
Indication:
In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Last updated September 25, 2026
Status:
Negotiation on hold
Manufacturer:
LEO Pharma Inc.
Indication:
Generalized pustular psoriasis (GPP)
Last updated September 25, 2026
Status:
Under consideration for negotiation
Manufacturer:
Janssen Inc.
Indication:
In combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent
Last updated September 23, 2026
Status:
Under consideration for negotiation
Manufacturer:
Ferring Canada Inc.
Indication:
For the treatment of mild to moderate ulcerative colitis
Last updated September 21, 2026